18889881171
Kalkine 0
countryflagUS

Ardelyx Inc

Healthcare US ARDX

3.725USD
0.03(0.68%)

Last update at 2025-06-12T18:50:00Z

Day Range

3.703.88
LowHigh

52 Week Range

3.1610.13
LowHigh

Fundamentals

  • Previous Close 3.70
  • Market Cap1579.34M
  • Volume5226270
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-60.44900M
  • Revenue TTM159.11M
  • Revenue Per Share TTM0.70
  • Gross Profit TTM 15.54M
  • Diluted EPS TTM-0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -67.19900M -158.16100M -94.31100M -94.63700M -91.29400M
Minority interest - - - - -
Net income -67.20700M -158.16500M -94.31300M -94.94000M -91.29800M
Selling general administrative 76.60M 72.30M 33.15M 24.27M 23.71M
Selling and marketing expenses - - - - -
Gross profit 48.04M 9.10M 7.43M 4.68M 2.14M
Reconciled depreciation 1.14M 1.44M 1.82M 2.50M 2.68M
Ebit -63.75900M -154.34600M -90.78000M -91.26300M -90.43800M
Ebitda -62.12600M -153.65900M -89.21200M -88.91100M -87.76000M
Depreciation and amortization 1.63M 0.69M 1.57M 2.35M 2.68M
Non operating income net other 1.63M 0.69M 1.57M 2.35M 3.19M
Operating income -63.75900M -154.34600M -90.78000M -91.26300M -90.94700M
Other operating expenses 115.92M 164.44M 98.35M 96.54M 93.55M
Interest expense 5.07M 4.50M 5.10M 5.73M 3.53M
Tax provision 0.00800M 0.00400M 0.00200M 0.30M 0.00400M
Interest income - - - 5.79M 127.73M
Net interest income -5.07300M -4.50200M -5.09900M -5.72600M -3.53400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00800M 0.00400M 0.00200M 0.30M 0.00400M
Total revenue 52.16M 10.10M 7.57M 5.28M 2.61M
Total operating expenses 111.80M 163.44M 98.21M 95.94M 93.09M
Cost of revenue 4.12M 1.00M 0.14M 0.60M 0.47M
Total other income expense net -3.44000M -3.81500M -3.53100M -3.37400M 3.19M
Discontinued operations - - - - -
Net income from continuing ops -67.20700M -158.16500M -94.31300M -94.94000M -91.29800M
Net income applicable to common shares -67.20700M -158.16500M -94.31300M -94.94000M -91.29800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 297.58M 190.07M 149.91M 201.56M 259.78M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.41M 5.11M 17.61M 8.75M 4.11M
Total liab 130.76M 91.74M 67.30M 75.45M 73.13M
Total stockholder equity 166.82M 98.33M 82.62M 126.11M 186.66M
Deferred long term liab - - - - -
Other current liab 27.64M 19.93M 12.79M 12.33M 11.70M
Common stock 0.02M 0.02M 0.01M 0.00900M 0.00900M
Capital stock 0.02M 0.02M 0.01M 0.00900M 0.00900M
Retained earnings -846.20400M -780.13700M -712.93000M -554.76500M -460.45200M
Other liab - 20.28M 4.73M - -
Good will - - - - -
Other assets - 25.95M 1.15M 0.55M 0.31M
Cash 21.47M 96.14M 72.43M 91.03M 181.13M
Cash and equivalents - - - - -
Total current liabilities 50.39M 74.63M 57.55M 28.42M 22.22M
Current deferred revenue 7.18M 13.24M 4.73M 4.18M 4.54M
Net debt 34.51M -59.68000M -26.92400M -37.71400M -126.43500M
Short term debt 4.43M 30.61M 35.76M 6.28M 3.79M
Short long term debt - 26.71M 32.26M 4.17M 1.18M
Short long term debt total 55.98M 36.46M 45.50M 53.32M 54.70M
Other stockholder equity 1012.77M 878.50M 795.54M 680.87M 647.08M
Property plant equipment - 1.22M 15.11M 1.94M 3.44M
Total current assets 246.11M 154.48M 134.80M 195.24M 252.38M
Long term investments - - 0.00000M 2.11M -
Net tangible assets - 98.33M 82.62M 126.11M 186.66M
Short term investments 162.83M 27.77M 44.26M 95.45M 66.38M
Net receivables 22.03M 7.73M 0.50M - 0.75M
Long term debt 49.82M - - 46.62M 48.83M
Inventory 12.45M 3.28M 1.15M - -
Accounts payable 11.14M 10.86M 4.28M 5.63M 2.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.22M -0.05400M -0.00600M -0.00400M 0.02M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.01M 0.00900M 0.00900M
Preferred stock total equity - - - - -
Retained earnings total equity - -780.13700M -712.93000M -554.76500M -460.45200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 44.87M 25.06M 1.15M 0.55M 0.31M
Deferred long term asset charges - - - - -
Non current assets total 51.47M 35.58M 15.11M 6.32M 7.41M
Capital lease obligations 6.16M 9.75M 13.24M 2.53M 4.68M
Long term debt total - - - 46.62M 48.83M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 16.67M 52.81M -31.11800M 23.70M -29.58300M
Change to liabilities 21.36M -0.79900M 3.29M 0.45M -1.88300M
Total cashflows from investing activities 18.41M 50.95M -31.44200M 23.37M -29.89400M
Net borrowings -6.06700M -19.44400M -0.12500M -0.12500M 49.29M
Total cash from financing activities 75.34M 83.00M 22.78M 155.48M 103.55M
Change to operating activities 0.91M -10.62100M -7.03800M -5.93000M 1.37M
Net income -67.20700M -158.16500M -94.31300M -94.94000M -91.29800M
Change in cash 23.71M -18.60400M -90.10100M 102.36M 3.38M
Begin period cash flow 72.43M 91.03M 181.13M 78.77M 75.38M
End period cash flow 96.14M 72.43M 91.03M 181.13M 78.77M
Total cash from operating activities -70.04400M -152.55100M -81.43500M -76.48400M -70.27400M
Issuance of capital stock 71.62M 101.15M 21.05M 154.90M 53.77M
Depreciation 1.14M 1.44M 1.82M 2.50M 2.68M
Other cashflows from investing activities 1.80M - - 23.70M -29.58300M
Dividends paid - - - - -
Change to inventory -28.34600M -10.37100M -28.34600M -3.41000M 1.88M
Change to account receivables -7.23100M -0.50200M 0.75M 0.09M 10.71M
Sale purchase of stock 71.83M 102.55M 22.90M 155.10M 54.26M
Other cashflows from financing activities 36.75M 1.30M 1.85M 0.57M 49.78M
Change to netincome 10.18M 15.17M 11.40M 10.85M 9.64M
Capital expenditures 0.06M 1.87M 0.32M 0.33M 0.31M
Change receivables -7.23100M -0.50200M - 0.09M 10.71M
Cash flows other operating -1.89600M -8.67200M -4.04700M 4.60M 0.78M
Exchange rate changes - - - - -
Cash and cash equivalents changes 23.71M -18.60400M -90.10100M 102.36M 3.38M
Change in working capital -19.57500M -11.92200M -3.21300M 2.98M 9.35M
Stock based compensation 10.75M 12.04M 10.58M 9.94M 9.23M
Other non cash items 4.84M 4.25M 3.37M 3.30M 0.79M
Free cash flow -70.09900M -154.41800M -81.75900M -76.80900M -70.58500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARDX
Ardelyx Inc		 0.03 0.68% 3.73 - - 13.20 9.85 12.17 -27.3593
NVO
Novo Nordisk A/S		 2.11 2.68% 80.84 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 2.40 3.07% 80.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 6.68 1.48% 459.12 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.42 1.05% 524.02 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Inc

400 Fifth Avenue, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Michael G. Raab Pres, CEO & Director 1965
Mr. Justin A. Renz CPA, M.S.T., MBA, MST CFO & Treasurer 1972
Ms. Elizabeth A. Grammer Chief Legal & Admin. Officer and Sec. 1964
Mr. David P. Rosenbaum Chief Devel. Officer 1961
Mr. Robert C. Blanks Chief Regulatory Affairs & Quality Assurance Officer 1960
Mr. Robert Felsch Sr. VP of Fin. & Chief Accounting Officer NA
Ms. Kimia Keshtbod Mang. of Corp. Communications & Investor Relations NA
Ms. Karen Harrigan Sr. Director Market Devel. NA
Dan Pavicich Sr. Director of Market Devel. NA
Ms. Susan Rodriguez Chief Commercial Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.